Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Pimitespib + Imatinib

Stage Phase 1

Sponsor Taiho Pharmaceutical

Class HSP90 inhibitor (with imatinib)

Target HSP90

Target KIT (TEC-0117)

Sources

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/40368739/

PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.

Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05245968

A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT05245968

Registry NCT05245968

Phase Phase 1

Status Active, not recruiting

Enrollment 78

Start 2021-12-01

Primary completion 2026-12

Study completion 2026-12

Catalyst Primary completion. 12.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.